2 Consumer Staples Stocks to Buy in February 2026

Coca-Cola and Altria are presented as defensive, income-oriented plays: Coca-Cola reported organic revenue growth of 5% in 2025, expects 4%–5% growth in 2026, pays a forward yield of 2.6%, has increased its dividend for 63 consecutive years, and trades at ~25x forward earnings; its capital-light concentrate model supports stable margins. Altria grew adjusted EPS ~4% in 2025, guides to 2.5%–5.5% EPS growth in 2026, targets at least $5 billion in smoke-free revenues by 2028 (bolstered by the 2023 acquisition of NJOY), yields ~6.3%, has raised its dividend 60 times over 56 years, and trades near 12x forward earnings.

Analysis

Market structure: Coca‑Cola (KO) and Altria (MO) are direct beneficiaries as defensive, cash‑generating staples amid a high‑PE market; KO's capital‑light concentrate model (25x forward EPS, organic rev +5% in 2025, guidance 4–5% for 2026) preserves margins, while MO (12x forward, 6.3% yield) uses pricing, buybacks and NJOY to offset volume declines. Losers are pure soda/smoke incumbents without product diversification or pricing power; smaller independent beverage/tobacco players face margin pressure. Cross‑asset: flows into staples should modestly tighten IG spreads and push Treasury demand lower for duration seekers; KO's global cash flow cushions FX swings, MO's U.S. focus limits currency exposure; input commodities (aluminum, sugar) remain moderate drivers of margin volatility.

Risk assessment: Tail risks include regulatory shocks (FDA e‑cig rulings or flavor bans), large litigation verdicts, or a material slowdown that erodes pricing pass‑through; quantify: MO needs ~ $5bn smoke‑free sales by 2028 to hit its transformation targets — missing that by >40% would impair rerating. Timing: days–weeks for news (FDA announcements, quarterly reports), months for adoption curves and bottler disputes, years for secular demand decline in cigarettes/soda. Hidden dependencies: KO depends on independent bottlers' margin/financing health; MO depends on buyback funding and consumer adoption of smoke‑free products. Catalysts: FDA approvals/decisions (next 30–90 days), KO bottler pricing agreements, commodity spikes.

Trade implications: Direct plays — establish a 2.5% core long in KO (target +10–15% out to 12–18 months, stop‑loss 12% below entry) for stable dividend+growth, and a smaller 1.5% tactical long in MO to capture 6.3% yield and potential re‑rating if NJOY scales (hold 6–12 months). Pair trade — long KO / short SPY (beta‑neutral dollar hedge) to harvest defensive premium for 3–9 months; alternative: long MO vs short a small‑cap tobacco peer lacking smoke‑free exposure. Options — sell 3–6 month covered calls on MO to boost yield (collect premium at ~5–7% annualized) and buy 9–12 month KO LEAP puts (~5–7% notional) as tail protection if macro dislocation occurs. Rotate: overweight staples by +300–400bp vs benchmark for next 6–12 months; underweight cyclical consumer discretionary.

Contrarian angles: Consensus underweights potential upside from MO’s NJOY integration — if smoke‑free revenue hits >$2.5bn by 2026 (50% of 2028 run‑rate), MO could re‑rate from 12x to ~14–15x, implying 20–30% upside. Conversely, market may underprice KO's pricing power and brand leverage — KO falling below 2% organic growth would be a clearer signal to cut exposure. Historical parallels: tobacco re‑ratings post‑diversification (e.g., PM smoke‑free push) support upside; unintended consequences include accelerated regulation that could wipe out NJOY value or force higher provisioning. Trigger thresholds to watch: FDA rulings in next 60–90 days, KO organic growth <3% on any quarter, MO smoke‑free revenue <$1.5bn by end‑2026 — these should prompt position re‑size within 10 trading days.

Key Decisions for Investors

• Establish a 2.5% long position in KO (ticker: KO) as a defensive core holding; target +10–15% upside over 12–18 months and collect dividend (2.6%); implement a stop‑loss at 12% below entry and review after quarterly results within 30 days.
• Initiate a 1.5% tactical long in MO (ticker: MO) to capture 6.3% yield and upside from NJOY integration; sell 3–6 month covered calls (strike ~5%–10% OTM) to boost income; reassess if smoke‑free revenues < $1.5bn by end‑2026 or if FDA issues arise within 60–90 days.
• Trade a pair: go long KO and short SPY in equal dollar amounts to neutralize beta and harvest defensive premium for 3–9 months; increase long KO weight by 300–400bp relative to benchmark if market volatility (VIX) rises >20% and staples outperform.
• Buy 9–12 month protective LEAP puts on KO equal to ~5–7% notional as tail hedges for macro shock scenarios; buy 3–6 month OTM puts on MO (1% notional) around major FDA/regulatory events to hedge regulatory risk.
• Monitor three catalysts over next 90 days and act: (1) FDA rulings on e‑cigs (move to hedge/increase puts on MO if negative), (2) KO bottler pricing agreements/quarterly organic growth (trim KO if organic <3%), (3) commodity spikes (aluminum/sugar >15% YoY should prompt margin stress re‑pricing and position review).